A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis.
Chu-Yueh GuoDavid HoldenNicola VickaryousJonathan BestwickKatila GeorgeTatiana SayaliLucia BianchiMohammad WafaJulian GoldGavin GiovannoniPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)
No significant effect of famciclovir on EBV shedding was seen in this small pilot study. Given the low numbers, a small effect of famciclovir cannot be excluded. Salivary EBV shedding in this natalizumab-treated cohort was lower than in previous studies, which requires replication.